**1. Introduction**

Cervical cancer is one of the most common cancers among the female population with the fourth most common after breast, colorectal, and lung cancer. In 2018, there were approximately 570,000 new cases of cervical cancer with 311,000 deaths [1]. Treatment of cervical cancer is composed of surgery, radiotherapy and systemic treatment. Concurrent chemoradiation is the standard treatment for locally advanced cervical cancer (LACC) and the combination of external beam radiotherapy (EBRT) and brachytherapy (BT) maximizes the local control while minimizing the risk of toxicity. Standard EBRT should deliver a dose of 45–50.4 Gy to the whole pelvis encompassing the uterus, adnexal structures, parametria, and pelvic lymph nodes. With BT, various dose fraction schedules are used, applying a dose of 5.5–8 Gy by 3–5 fractions and the total combined dose with EBRT and BT should be in the range of 80–90 Gy [2]. From the publications of Han et al. and

Gill et al. BT is one of the major components for curative radiotherapy for LACC [3–5]. Completion of the radiation program within a suitable time is an important goal as it has a direct correlation to the outcome. The current recommendation is to finish the entire protocol of EBRT and BT within 8 weeks [2].
